Question of the Month – July 2020 Written by: Tommy Spain, MD, MPHAssociate Professor UT SouthwesternChildren’s Medical Center Dallas You are a pediatric pain management physician at a tertiary care pediatric hospital. Due to the overwhelming number of pediatric patients presenting to your hospital system complaining of headaches, you and your team have been asked to help the neurologists with the patient load. You have been seeing a 17 y/o female patient for the last three years for migraine headaches. She has been treated with numerous different preventives including topiramate, zonisamide, and nortriptyline with limited efficacy. She is interested in trying Aimovig (erenumab). Which of the following is NOT true: A. Aimovig functions as a monoclonal antibody blocking the calcitonin gene-related peptide receptor (CGRP). B. Your patient is a good candidate for Aimovig because she is over the age of 12 C. In the United Kingdom, Aimovig was rejected by the National Institute of Health and Care Excellence on the basis that its cost-effectiveness was not sufficiently proven. D. Aimovig can only be administered by subcutaneous injection.